Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Norman Wolmark"'
Autor:
Priya Rastogi, Charles E. Geyer, Rami Younan, Aman U. Buzdar, Ajit M. Desai, Virginie Fourchotte, Louis Fehrenbacher, Norman Wolmark, Eleftherios P. Mamounas, André Robidoux, Eduardo R. Pajon, E. Quinaux, Samuel A. Jacobs, Ibrahim A. Shalaby
Publikováno v:
Clinical Breast Cancer. 10:81-86
Background Neoadjuvant chemotherapy has become standard treatment for women with locally advanced breast cancer (LABC). Various regimens have explored the addition of newer agents to determine safety and efficacy. The aim of this phase II study was t
Autor:
Stefan Aebi, Martine Piccart, Norman Wolmark, Monica Castiglione-Gertsch, Mark Clemons, Irene Wapnir, Richard D. Gelber, Charles E. Geyer, Jürg Bernhard, Rudolf Maibach, Alan S. Coates, David Zahrieh, Joseph P. Costantino, André Robidoux, Stewart J. Anderson
Publikováno v:
Clinical Breast Cancer. 8:287-292
In this phase III, multinational, randomized trial, the International Breast Cancer Study Group, Breast International Group, and the National Surgical Adjuvant Breast and Bowel Project will attempt to define the effectiveness of cytotoxic therapy for
Autor:
Howard M. Gross, Erica Patocskai, André Robidoux, John W. Smith, Philip J. Stella, Jonathan Polikoff, Raymond S. Lord, Charles E. Geyer, Norman Wolmark, Bilal Ansari, Celine Mauquoi, Marc Buyse, George P. Keogh, Priya Rastogi, Eleftherios P. Mamounas, Sandra M. Swain, Samuel A. Jacobs, Alison Conlin
Publikováno v:
Clinical Breast Cancer. 17:48-54.e3
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LA
Autor:
Norman Wolmark, Marc Buyse, Sandra M. Swain, Juan G. Posada, Priya Rastogi, Elfetherios P. Mamounas, Eduardo R. Pajon, Charles E. Geyer, Marcia K. Liepman, Fanny Piette, Samuel A. Jacobs, Philip A. Dy, André Robidoux, Marianne K. Melnik
Publikováno v:
Clinical breast cancer. 11(4)
Background Bevacizumab with chemotherapy improves outcomes in patients with metastatic breast cancer (MBC). The purpose of this trial was to determine the activity and safety profile of neoadjuvant bevacizumab with chemotherapy in women with locally
Autor:
Norman Wolmark, Jong-Hyeon Jeong, Eleftherios P. Mamounas, Walter M. Cronin, Joseph P. Costantino, Barbara Harkins, Soonmyung Paik, Charles E. Geyer, D L Wickerham, Barry C. Lembersky
Publikováno v:
Clinical breast cancer. 7(5)
Aromatase Inhibitors as Adjuvant Therapy Adjuvant hormonal therapy significantly improves disease-free and overall survival in patients with stage I, II, or III breast cancer and hormone receptor–positive tumors.1,2 For some time, 5 years of adjuva
Autor:
Joseph P. Costantino, Walter M. Cronin, D. Lawrence Wickerham, Norman Wolmark, Victor G. Vogel
Publikováno v:
Clinical breast cancer. 3(2)
Tamoxifen reduced the risk of invasive breast cancer by 49% among women at increased risk for breast cancer in the Breast Cancer Prevention Trial P-1, and raloxifene reduced breast cancer incidence by more than 70% in the Multiple Outcomes of Raloxif